ELVN · NASDAQ
Enliven Therapeutics (ELVN) Stock Price & Fundamentals
Enliven Therapeutics (ELVN) closed at $263.58 on Oct 9, 2026, up 0.40% from the previous close of $262.52.
Share price, past year
1Y +44.29%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $263.58 |
| Sep 30, 2026 | $261.31 |
| Aug 31, 2026 | $250.28 |
| Jul 31, 2026 | $242.16 |
| Jun 30, 2026 | $250.65 |
| May 29, 2026 | $246.10 |
| Apr 30, 2026 | $243.59 |
| Mar 31, 2026 | $223.11 |
| Feb 27, 2026 | $210.51 |
| Jan 30, 2026 | $204.51 |
| Dec 31, 2025 | $191.38 |
| Nov 28, 2025 | $203.30 |
| Oct 31, 2025 | $200.64 |
Key statistics
- Market cap
- $19.31B
- EPS (TTM)
- −$1.64
- Net income (TTM)
- −$105.93M
- Shares outstanding
- 73.3M
- 52-week range
- $182.67 – $263.58
Enliven Therapeutics's market cap is $19.31B, based on a share price of $263.58 and 73.3M shares outstanding as of Jun 30, 2026.
Financials
Enliven Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Enliven Therapeutics reported a net loss of $103.69M in fiscal 2025.
Company profile
- Name
- Enliven Therapeutics, Inc.
- Ticker
- ELVN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 205 Park Road, Burlingame, CA 94010
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001672619
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 12, 2026
- Jun 11, 2026
- Jun 10, 2026
- May 7, 2026
- May 7, 2026
- Mar 3, 2026
Frequently asked questions
What is Enliven Therapeutics's stock price?
Enliven Therapeutics (ELVN) closed at $263.58 on Oct 9, 2026, up 0.40% from the previous close of $262.52.
What is Enliven Therapeutics's market cap?
Enliven Therapeutics's market cap is $19.31B, based on a share price of $263.58 and 73.3M shares outstanding as of Jun 30, 2026.
Does Enliven Therapeutics pay a dividend?
Enliven Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Enliven Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures